Bleeding Disorder News and Research

RSS
Inspiration, Ipsen receive FDA Fast Track designation for OBI-1 to treat AHA

Inspiration, Ipsen receive FDA Fast Track designation for OBI-1 to treat AHA

Hemostatic testing may explain heavy menstrual bleeding

Hemostatic testing may explain heavy menstrual bleeding

Pfizer Hemophilia donates more than 35M IUs of recombinant factor IX therapy to WFH

Pfizer Hemophilia donates more than 35M IUs of recombinant factor IX therapy to WFH

Physical activity associated with increased risk of bleeding in children with hemophilia

Physical activity associated with increased risk of bleeding in children with hemophilia

Dexamethasone use during tonsillectomy not associated with excessive bleeding in children

Dexamethasone use during tonsillectomy not associated with excessive bleeding in children

Roundup: Ore. insurance CO-OP readies coverage; N.J. Medicaid liabilities hurt state's fiscal outlook; Wis. AG appeals collective bargaining ruling

Roundup: Ore. insurance CO-OP readies coverage; N.J. Medicaid liabilities hurt state's fiscal outlook; Wis. AG appeals collective bargaining ruling

Inspiration receives FDA clinical hold order for IB1001 phase III studies on hemophilia B

Inspiration receives FDA clinical hold order for IB1001 phase III studies on hemophilia B

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Bayer commences enrollment in BAY94-9027 Phase II/III trial for hemophilia A

Bayer commences enrollment in BAY94-9027 Phase II/III trial for hemophilia A

New U-M hESC lines now available for federally-funded research

New U-M hESC lines now available for federally-funded research

CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B

CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B

What are vitamins?

What are vitamins?

Positive long-term outcome data for chronic ITP patients treated with rituxamab

Positive long-term outcome data for chronic ITP patients treated with rituxamab

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

CSL Behring commits donations to World Federation of Hemophilia GAP program

CSL Behring commits donations to World Federation of Hemophilia GAP program

Inspiration submits IB1001 BLA with FDA for treatment of hemophilia B

Inspiration submits IB1001 BLA with FDA for treatment of hemophilia B

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

Bayer receives FDA approval for lower dose formulation of ANGELIQ

Bayer receives FDA approval for lower dose formulation of ANGELIQ

FDA grants orphan drug designation to CSL Behring's rVIIa-FP

FDA grants orphan drug designation to CSL Behring's rVIIa-FP

CSL Behring announces results of rIX-FP Phase I study on hemophilia B

CSL Behring announces results of rIX-FP Phase I study on hemophilia B